# OnCo record iberdomide (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/iberdomide/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "iberdomide" ;
  schema:name "Iberdomide"@en ;
  schema:description "Iberdomide is a far more potent successor to lenalidomide, now in phase 3 as post-transplant maintenance and in relapsed disease."@en ;
  schema:url <https://onco.cc/drugs/iberdomide/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Iberdomide> ;
  onco:status "approved" ;
  onco:modality "CELMoD (cereblon E3 ligase modulator)" ;
  schema:alternateName "Zenbexus" ;
  onco:approval "US 2026: Multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with subcutaneous daratumumab and dexamethasone (Zenbexus, label effective 13 August 2026)" ;
  onco:acceleratedApproval "US 2026-08-13: In combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/celmods/> ;
  onco:drugs <https://onco.cc/drugs/lenalidomide/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:trials <https://onco.cc/trials/nct05827016/>, <https://onco.cc/trials/nct04975997/>, <https://onco.cc/trials/nct05583617/>, <https://onco.cc/trials/nct06892522/>, <https://onco.cc/trials/nct02773030/> .